- First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumorsWu, J.; Zhang, J.; Li, H.; Wang, X.; Zhang, Q. Y.; Shi, Y.; Yan, M.; Pan, Y.; Shen, A.; Chen, Q.; Rao, Q.; Wei, H.; Li, C.; Yang, L.; Huang, Q.; Cao, Z.; Wu, Q.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumorsZhou, Q.; Wu, Y-L.; Li, J.; Liu, A.; Cui, J.; Kuboki, Y.; Yamamoto, N.; Han, S-W.; Lin, G.; Sun, J-M.; Wu, L.; Zhu, Z.; Shuang, J.; Qiu, F.; Shi, W.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumorsWang, Yakun; Gong, Jifang; Lin, Rongbo; Zhao, Shen; Wang, Jufeng; Wang, Qianli; Zhang, Yanqiao; Su, Dan; Zhang, Jingdong; Dong, Qian; Lin, Ling; Tian, Wen; Chen, Ying; Yang, Yang; Zhang, Xueyuan; Wan, Xuechao; Gao, Jinfeng; An, Na; Jansen, Valerie Malyvanh; Shen, LinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3-targeting antibody-drug conjugate, in patients with advanced solid tumor
3被引4阅读
